SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS DURING THE MONTH OF RAMADAN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A TERTIARY CARE CENTRE IN KARACHI, PAKISTAN

Aisha Sheikh, Bhagwan Das, Saadia Sattar, Najmul Islam

ABSTRACT

OBJECTIVE: To assess the safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) during the fasting month of Ramadan, in a real-life scenario, by finding the frequency and severity of severe hypoglycemia, hyperglycemia, dehydration, or diabetic ketoacidosis (DKA).

METHODS: This prospective, observational study was conducted at Aga Khan University Hospital, Karachi, Pakistan from 15th March to 30th June 2021. Known cases of Type 2 Diabetes Mellitus (T2DM), aging more than 18 years old and already on stable doses of SGLT2-I were included in study. Patients were assessed at one month before and within six weeks after Ramadan for the outcome measures.

RESULTS: Total of 101 participants were enrolled and because of pandemic, we were able to collect complete data on 84 (83.2%) participants. Majority (n=44; 52.4%) of participants were males. Mean age of patients was 52.4±9.5 years with an average duration of T2DM was 11.5±6.5 years. Most of the study participants (n=54; 64.3%) were on Empagliflozin (mean-dose=14.7±7.1 mg/day) and 30 (35.7%) participants were on Dapagliflozin (mean-dose=8.2±2.7 mg/day). Only six patients (7.1%) reported having mild hypoglycemia. No study participant had any severe hypoglycemia, hyperglycemia, dehydration or DKA that would have required hospital admission. Changes observed were in the HbA1c (7.6±1.2% from 7.9±2.4%, p=0.34), weight (78.1±13.1 Kgs from 78.7±13.4 Kgs, p=0.23) and in creatinine (0.9±0.2 mg/dl from 0.9±0.4 mg/dl, p<0.09) within six weeks post Ramadan.

CONCLUSION: SGLT2-I agents are safe and effective during the month of Ramadan in Pakistani patients with T2DM, without any additional adverse events.

KEY WORDS: Diabetes Mellitus, Type 2 (MeSH); Sodium-Glucose Transport Proteins (MeSH); Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) (Non-MeSH); Ramadan (Non-MeSH); Empagliflozin (Non-MeSH); Dapagliflozin (Non-MeSH); Hypoglycemia (MeSH); Hyperglycemia (MeSH); Dehydration (MeSH); Diabetic Ketoacidosis (MeSH).


CONFICT OF INTEREST

Authors declared no conflict of interest

GRANT SUPPORT AND FINANCIAL DISCLOSURE

This study is supported by research grant from Pakistan Endocrine Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non Commercial 2.0 Generic License.